AUROBAC THERAPEUTICS is a biopharmaceutical company dedicated to the fight against severe bacterial infections and their consequences

      Our Vision      >      

Medical Needs

Antimicrobial Resistance (AMR) has become one of the world’s greatest threats to public health, with over 1,27 million deaths worldwide today, and an estimated 10 million deaths a year by 2050. Because of AMR, infections are increasingly difficult to treat, and the resulting medical needs are high.

It is estimated that 63.5% of cases of antibiotic-resistant bacterial infections are healthcare-associated. Acute respiratory infections associated with healthcare (HAP/VAP) continue to be a frequent complication of hospital care, accounting for 22% of all nosocomial infections. These respiratory infections are the most common source of infections leading to sepsis, accounting for 47% of cases.

Research & Development

We focus all our efforts on identifying and developing innovative products with the ability to address clear unmet medical needs associated to bacterial infections and increasing AMR, in acute hospital settings, aligned with viable clinical development plans based on a precision medicine concept.

Learn more


Our Team

Driven by a shared vision, our team is at the forefront of developing precision medicines to combat AMR and infectious diseases.

All members

AUROBAC THERAPEUTICS is proud to be a member of the BEAM Alliance

AUROBAC ©2024 – Legal NoticePrivacy StatementPhoto Credits